Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Cranbury, USA
1 Cedar Brook Drive
Cranbury, NJ, 08512
USA

People

Board Member
Board Member
Chairman & Chief Executive Officer
Chief Medical Officer
Chief Business Officer

Acquisitions

Funding

TOTAL $49.9M
FUNDING TOTAL $49.9M
Venture Round, 11/2010
$31.3M
Venture Round, 7/2012
$18.6M
DEBT TOTAL $25M
Debt, 12/2013
$15M
Debt, 12/2013
MidCap Financial
Oxford Finance Corporation
Silicon Valley Bank
$10M

Tags

Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

Recent Milestones

Videos

Screenshots

Amicus Therapeutics screenshot
Above: Amicus Therapeutics
Uploaded: 3/11/13

Sources

  1. Amicus Therapeutics acquires Callidus Biopharma, announces financing (finance.yahoo.com) [edit]
  2. SEC (sec.gov) [edit]
  3. SEC (sec.gov) [edit]
  4. SEC (sec.gov) [edit]
  5. Amicus Therapeutics completes debt financing of up to $25m (processandproduction.pharmaceutical-business-review.com) [edit]
Edit This Page
Last Edited 3/3/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy